Building on these findings of others, and to further explore a mechanistic role of MuRF1 in the skeletal muscle of tumor-bearing hosts, we tested the requirement of MuRF1 for pancreatic cancer-induced skeletal muscle atrophy and weakness, and further aimed to identify the MuRF1 skeletal muscle ubiquitinome during the progression of cancer-induced muscle atrophy. Here, TRIM63 is linked to familial pancreatic carcinoma.